Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases

被引:0
作者
Saha, Punnag [1 ]
Hartmann, Phillipp [1 ,2 ]
机构
[1] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA
[2] Rady Childrens Hosp, Div Gastroenterol Hepatol & Nutr, San Diego, CA 92123 USA
基金
美国国家卫生研究院;
关键词
CLDs; ALD; MASLD; PSC; IBD; gut microbiome; FARNESOID-X-RECEPTOR; PRIMARY SCLEROSING CHOLANGITIS; INFLAMMATORY-BOWEL-DISEASE; ACTIVE ULCERATIVE-COLITIS; LIPOPOLYSACCHARIDE-BINDING PROTEIN; CHAIN FATTY-ACIDS; NONALCOHOLIC STEATOHEPATITIS; OBETICHOLIC ACID; BILE-ACIDS; INTESTINAL PERMEABILITY;
D O I
10.3390/microorganisms13061188
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatobiliary and gastrointestinal conditions, including chronic liver diseases and inflammatory bowel disease, are associated with significant morbidity and mortality globally. While the pathophysiology and symptoms vary from one disease to another, aberrations of the gut microbiome with deleterious microbial products affecting the intestinal barrier are common in patients suffering from these diseases. In this review, we summarize changes in the gut microbiome associated with various disease states and detail their role in gut barrier disruption and in modulating disease progression. Further, we discuss therapeutic interventions and precision medicine approaches targeting the microbiome, which have shown promise in alleviating these chronic illnesses in mouse models and patients.
引用
收藏
页数:30
相关论文
共 236 条
[1]   Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease [J].
Adams, Leon A. ;
Wang, Zhengyi ;
Liddle, Chris ;
Melton, Phillip E. ;
Ariff, Amir ;
Chandraratna, Harsha ;
Tan, Jeremy ;
Ching, Helena ;
Coulter, Sally ;
de Boer, Bastiaan ;
Christophersen, Claus T. ;
O'Sullivan, Therese A. ;
Morrison, Mark ;
Jeffrey, Gary P. .
LIVER INTERNATIONAL, 2020, 40 (06) :1356-1365
[2]   Heavy arch: from inflammatory bowel diseases to metabolic disorders [J].
Adolph, Timon E. ;
Meyer, Moritz ;
Jukic, Almina ;
Tilg, Herbert .
GUT, 2024, 73 (08) :1376-1387
[3]   Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study [J].
Agraib, Lana M. ;
Yamani, Mohammed I. ;
Tayyem, Reema ;
Abu-Sneineh, Awni Taleb ;
Rayyan, Yaser Mohammed .
CLINICAL NUTRITION ESPEN, 2022, 51 :83-91
[4]   Health Benefits of Prebiotics, Probiotics, Synbiotics, and Postbiotics [J].
Al-Habsi, Nasser ;
Al-Khalili, Maha ;
Haque, Syed Ariful ;
Elias, Moussa ;
Olqi, Nada Al ;
Al Uraimi, Tasnim .
NUTRIENTS, 2024, 16 (22)
[5]   Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial [J].
Allegretti, Jessica R. ;
Kassam, Zain ;
Carrellas, Madeline ;
Mullish, Benjamin H. ;
Marchesi, Julian R. ;
Pechlivanis, Alexandros ;
Smith, Mark ;
Gerardin, Ylaine ;
Timberlake, Sonia ;
Pratt, Daniel S. ;
Korzenik, Joshua R. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (07) :1071-1079
[6]   Current Trends and Challenges of Fecal Microbiota Transplantation-An Easy Method That Works for All? [J].
Almeida, Catia ;
Oliveira, Rita ;
Baylina, Pilar ;
Fernandes, Ruben ;
Teixeira, Fabio G. ;
Barata, Pedro .
BIOMEDICINES, 2022, 10 (11)
[7]   Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases [J].
Almeqdadi, Mohammad ;
Gordon, Fredric D. .
GASTRO HEP ADVANCES, 2024, 3 (03) :344-352
[8]  
Altun HK, 2022, J GASTROINTEST LIVER, V31, P417, DOI [10.15403/jgld-4345, 10.15403/JGLD-4345]
[9]  
Amiriani Taghi, 2020, Middle East J Dig Dis, V12, P27, DOI 10.15171/mejdd.2020.160
[10]   The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases [J].
An, Lingxuan ;
Wirth, Ulrich ;
Koch, Dominik ;
Schirren, Malte ;
Drefs, Moritz ;
Koliogiannis, Dionysios ;
Niess, Hanno ;
Andrassy, Joachim ;
Guba, Markus ;
Bazhin, Alexandr, V ;
Werner, Jens ;
Kuehn, Florian .
JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (03) :671-683